BACKGROUND: Vascular reconstruction during pancreaticoduodenectomy is increasingly utilized to improve pancreatic cancer resectability. However, few multi-institutional studies have evaluated the morbidity and mortality of arterial and venous reconstruction during this procedure. METHODS: A retrospective analysis was performed utilizing the targeted pancreas module of the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) for pancreaticoduodenectomy from 2014 to 2015. Demographics, comorbidities, and 30-day outcomes for patients who underwent venous or arterial reconstruction and both were compared to no reconstruction. RESULTS: A total of 3002 patients were included in our study: 384 with venous reconstruction, 52 with arterial, 81 with both, and 2566 without. Compared to patients without reconstruction, those who underwent venous reconstruction had more congestive heart failure (1.8% vs 0.2%, P < 0.01), those with arterial reconstruction had higher rates of pulmonary disease (11.5% vs. 4.5%, P = 0.02), and neoadjuvant chemotherapy was more common in both venous (34% vs 12%, P < 0.01) and arterial reconstruction (21% vs 12%, P = 0.04). In multivariable analysis, there was no increase in morbidity or mortality following venous reconstruction. However, arterial reconstruction was associated with increased 30-day mortality with an odds ratio (OR): 6.7, 95%; confidence interval (CI): 1.8-25. Morbidity was increased as represented with return to the operating room (OR: 4.5, 95%; CI: 1.5-15), pancreatic fistula (OR: 4.4, 95%; CI: 1.7-11), and reintubation (OR: 3.9, 95%; CI: 1.1-14). CONCLUSIONS: Venous reconstruction during pancreaticoduodenectomy does not increase perioperative morbidity or mortality and should be considered for patients previously considered to be unresectable or those where R0 resection would otherwise not be possible due to venous involvement. Careful consideration should be made prior to arterial reconstruction given the significant increase in perioperative complications and death within 30 days.
BACKGROUND: Vascular reconstruction during pancreaticoduodenectomy is increasingly utilized to improve pancreatic cancer resectability. However, few multi-institutional studies have evaluated the morbidity and mortality of arterial and venous reconstruction during this procedure. METHODS: A retrospective analysis was performed utilizing the targeted pancreas module of the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) for pancreaticoduodenectomy from 2014 to 2015. Demographics, comorbidities, and 30-day outcomes for patients who underwent venous or arterial reconstruction and both were compared to no reconstruction. RESULTS: A total of 3002 patients were included in our study: 384 with venous reconstruction, 52 with arterial, 81 with both, and 2566 without. Compared to patients without reconstruction, those who underwent venous reconstruction had more congestive heart failure (1.8% vs 0.2%, P < 0.01), those with arterial reconstruction had higher rates of pulmonary disease (11.5% vs. 4.5%, P = 0.02), and neoadjuvant chemotherapy was more common in both venous (34% vs 12%, P < 0.01) and arterial reconstruction (21% vs 12%, P = 0.04). In multivariable analysis, there was no increase in morbidity or mortality following venous reconstruction. However, arterial reconstruction was associated with increased 30-day mortality with an odds ratio (OR): 6.7, 95%; confidence interval (CI): 1.8-25. Morbidity was increased as represented with return to the operating room (OR: 4.5, 95%; CI: 1.5-15), pancreatic fistula (OR: 4.4, 95%; CI: 1.7-11), and reintubation (OR: 3.9, 95%; CI: 1.1-14). CONCLUSIONS: Venous reconstruction during pancreaticoduodenectomy does not increase perioperative morbidity or mortality and should be considered for patients previously considered to be unresectable or those where R0 resection would otherwise not be possible due to venous involvement. Careful consideration should be made prior to arterial reconstruction given the significant increase in perioperative complications and death within 30 days.
Authors: Kaitlyn J Kelly; Emily Winslow; David Kooby; Neha L Lad; Alexander A Parikh; Charles R Scoggins; Syed Ahmad; Robert C Martin; Shishir K Maithel; H J Kim; Nipun B Merchant; Clifford S Cho; Sharon M Weber Journal: J Gastrointest Surg Date: 2013-04-26 Impact factor: 3.452
Authors: Anthony W Castleberry; Rebekah R White; Sebastian G De La Fuente; Bryan M Clary; Dan G Blazer; Richard L McCann; Theodore N Pappas; Douglas S Tyler; John E Scarborough Journal: Ann Surg Oncol Date: 2012-08-30 Impact factor: 5.344
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Mathias Worni; Anthony W Castleberry; Bryan M Clary; Beat Gloor; Elias Carvalho; Danny O Jacobs; Ricardo Pietrobon; John E Scarborough; Rebekah R White Journal: JAMA Surg Date: 2013-04 Impact factor: 14.766
Authors: Maximilian Bockhorn; Faik G Uzunoglu; Mustapha Adham; Clem Imrie; Miroslav Milicevic; Aken A Sandberg; Horacio J Asbun; Claudio Bassi; Markus Büchler; Richard M Charnley; Kevin Conlon; Laureano Fernandez Cruz; Christos Dervenis; Abe Fingerhutt; Helmut Friess; Dirk J Gouma; Werner Hartwig; Keith D Lillemoe; Marco Montorsi; John P Neoptolemos; Shailesh V Shrikhande; Kyoichi Takaori; William Traverso; Yogesh K Vashist; Charles Vollmer; Charles J Yeo; Jakob R Izbicki Journal: Surgery Date: 2014-02-07 Impact factor: 3.982
Authors: Caitlin A McIntyre; Noah A Cohen; Debra A Goldman; Mithat Gonen; Eran Sadot; Eileen M O'Reilly; Anna M Varghese; Kenneth H Yu; Vinod P Balachandran; Kevin C Soares; Michael I D'Angelica; Jeffrey A Drebin; T P Kingham; Peter J Allen; Alice C Wei; William R Jarnagin Journal: J Surg Oncol Date: 2021-10-31 Impact factor: 3.454
Authors: Caitlin A McIntyre; Constantinos P Zambirinis; Alessandra Pulvirenti; Joanne F Chou; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Murray F Brennan; Jeffrey A Drebin; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2020-05-25 Impact factor: 5.344